Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Profile of a Pioneer: Robert A. Good
Often referred to as the founder of modern immunology, Robert Alan Good, MD, PhD (Figure 1) was an exceptionally productive immunologist and gifted physician. His discoveries distinguished the lymphoid lineages responsible for cell-mediated and humoral immunity, and he played a seminal role in the science and application of allogeneic marrow transplantation for curative treatment of genetic and acquired diseases of immunity and hematopoiesis. He was born in Crosby, MN, the second of four sons of teacher parents. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Richard J. O'Reilly Tags: Reflections Source Type: research

Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma
The recent introduction of chimeric antigen receptor T cell therapy (CAR T) into clinical practice has radically shifted the treatment paradigm of relapse/refractory B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) .1 The current commercially available products including axicabtagene ciloleucel (axi-cel) ,2 tisagenlecleucel (tisa-cel) ,3 and lisocabtagene maraleucel (liso-cel) 4,5 for NHL and idcabtagene vicleucel (ide-cel) 6,7 and ciltacabtagene autoleucel f d(cilta-cel) 8 for MM have shown impressive response rates and survival outcomes in heavily pretreated patients who would otherwise have very limited treat...
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Danai Dima, Craig S. Sauter Tags: The Bottom Line Source Type: research

Thrombopoietin Agonism to Promote Platelet Engraftment Following Hematopoietic Stem Cell Transplantation: Promising, but Not Ready for Primetime
In this issue of TCT, Fu and colleagues report the results of a randomized clinical trial conducted in China comparing thrombopoietic support using recombinant human thrombopoietin (rhTPO) with observation to promote platelet engraftment in patients receiving haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplantation cyclophosphamide for the treatment of severe aplastic anemia (SAA).1 The trial enrolled 55 patients, randomized 1:1 to rhTPO or observation. The authors report successful hematopoietic reconstitution in all patients, but significantly faster platelet engraftment in patients randomi...
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Hanny Al-Samkari Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Transplant-associated Altered Mentation and Encephalopathy (TAME): A New Classification for Acute Neurocognitive Changes Associated with Hematopoietic Cell Transplantation from the ASTCT Committee on Practice Guidelines
Acute encephalopathy, manifesting clinically as delirium, is a common but often unrecognized complication of hematopoietic cell transplant (HCT). Delirium is found in patients of any age and observed after autologous or allogeneic HCT. While primarily studied during initial transplant hospitalizations among recipients of myeloablative conditioning, recent HCT investigations have identified delirium later posttransplant and among those who received reduced intensity conditioning. Acute encephalopathy can be driven by infectious complications, medications, tissue damage and/or organ dysfunction. (Source: Biology of Blood and...
Source: Biology of Blood and Marrow Transplantation - April 23, 2024 Category: Hematology Authors: G. Meyers, J. Bubalo, E. Eckstrom, K. Winsnes, P.A. Carpenter, A. Artz, R.J. Lin Source Type: research

The application of umbilical cord blood-derived platelet gel for skin ulcers associated with chronic graft-versus-host disease in pediatrics: A randomized trial
Hematopoietic stem cell transplantation (HSCT) is a definitive therapy for a myriad of malignant and non-malignant hematopoietic, immune-related, and lysosomal storage disorders1, 2. However, graft-versus-host disease (GVHD), the main complication of allogeneic HSCT (allo-HSCT), significantly compromises the survival and the quality of life of recipients3-5. Accordingly, chronic GVHD (cGVHD) afflicts 20-50% of allo-HSCT cases6 and is one of the principal etiologies of morbidity and compromised quality of life, especially among pediatric patients7, 8. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 23, 2024 Category: Hematology Authors: Rashin Mohseni, Pouya Mahdavi Sharif, Abbas Khosravi, Ahmad Reza Taheri, Maryam Behfar, Morteza Zarrabi, Leila Jafari, Fahimeh Jafari, Zeynab Nikfetrat, Parisa Naji, Amir Ali Hamidieh Source Type: research

Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada
Acute myeloid leukemia (AML) is considered a genetically heterogeneous disease, with different AML subtypes associated with distinct outcomes.1 Internal tandem duplications of the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are present in approximately 25% of patients with AML and are associated with higher rates of relapse and shorter overall survival.2,3 In these patients, allogeneic hematopoietic cell transplantation (alloHCT) represents a potentially curative treatment option.4 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 23, 2024 Category: Hematology Authors: Bhavik J. Pandya, Linda J Burns, Tao Wang, Bin Xie, Maelys Touya, James Spalding, Alana Block, Gaston Kuperman, Christopher Young Source Type: research

Treosulfan- versus busulfan-based conditioning in allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a single-center retrospective propensity score-matched cohort study
High-risk myeloid malignancies, particularly those associated with adverse cytogenetic and molecular characteristics, present a challenging therapeutic scenario. The increased prevalence of these diseases in older individuals, who often have comorbidities or are considered frail, their aggressive nature, and poor survival rates even after allogeneic hematopoietic cell transplantation (HCT), demand innovative approaches.1 Traditional myeloablative conditioning (MAC), typically based on total body irradiation (TBI) or high-dose busulfan, has been associated with significant organ toxicity and high non-relapse mortality (NRM)...
Source: Biology of Blood and Marrow Transplantation - April 20, 2024 Category: Hematology Authors: Ivan Pasic, Tommy Alfaro Moya, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson Source Type: research

Persistent or new cytopenias predict relapse better than routine bone marrow aspirate evaluations after hematopoietic cell transplantation for acute leukemia or myelodysplastic syndrome in children and young adult patients
Allogeneic hematopoietic cell transplantation (alloHCT) offers a curative approach to children with high-risk leukemia, refractory leukemia, and myelodysplastic syndrome (MDS) with survival rates ranging from 50% to 70%.1,2. Relapse within the first two years after HCT is the most common cause of treatment failure.1,3,4 Among pediatric transplantation providers there is growing consensus regarding appropriate patient and donor selection, cytoreduction and source of stem cells.2 Although detection of bone marrow (BM) minimal residual disease (MRD) by multiparameter flow cytometry (MFC, MFC-MRD) or next generation sequencing...
Source: Biology of Blood and Marrow Transplantation - April 19, 2024 Category: Hematology Authors: Nancy A. Kernan, Elizabeth Klein, Audrey Mauguen, Joanne Torok-Castanza, Susan E. Prockop, Andromachi Scaradavou, Kevin Curran, Barbara Spitzer, Maria Cancio, Julie Ruggiero, Jennifer Allen, Andrew Harris, Joseph Oved, Richard J. O'Reilly, Jaap Jan Boelen Source Type: research

Bone Marrow Harvest: A White Paper of Best Practices by the NMDP Marrow Alliance
Allogeneic hematopoietic cell transplantation (alloHCT) is a life-saving procedure for treatment of a variety of devastating diseases. NMDP was established in 1987 to facilitate alloHCT from anonymous, volunteer, adult unrelated donors (URDs) to patients in need. Bone marrow (BM) has been used as a source of hematopoietic stem cells (HSC) from the 1960s1 and is collected via a BM harvest (BMH) procedure. There has been a significant decrease in the use of BM as a stem cell source since the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 17, 2024 Category: Hematology Authors: Mark A. Murakami, Laura Connelly-Smith, Thomas Spitzer, Adetola A. Kassim, Sam L. Penza, Monzr M. Al Malki, James Mason, Chelsa Tourville, Brandon Magliocco, Jacklyn Barten, Hope Guidry-Groves, Jamie Margolis, Steven M. Devine, Wolfgang P. Rennert, Heathe Source Type: research

Lymphocyte Crossmatch Testing or Donor HLA-DP and -DQ Allele Typing Effectiveness in Single Cord Blood Transplantation for Patients with Anti-HLA antibodies Other Than Against HLA-A, -B, -C, and -DRB1
Graft failure or engraftment delay is a serious complication of hematopoietic stem cell transplantation and contributes to increased non-relapse mortality (NRM). The risk of graft failure is particularly higher in cord blood transplantation (CBT), due to its relatively low number of infused cells1-4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 17, 2024 Category: Hematology Authors: Makoto Osada, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Shigeyoshi Makino, Yuki Asano-Mori, Go Yamamoto, Shuichi Taniguchi, Atsushi Wake, Naoyuki Uchida Source Type: research

Listeria monocytogenes Infections in Hematopoietic Cell Transplantation Recipients: Clinical Manifestations and Risk Factors. A Multinational Retrospective Case-Control Study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Listeria is a facultative intracellular bacillus that can infect humans following ingestion of contaminated food [1]. There are several species of Listeria, of which Listeria monocytogenes (LM) and (rarely) Listeria ivanovii can cause infection in humans [2]. Following gastrointestinal infection, Listeria can spread to the bloodstream and brain and is one of the most common etiologies of central nervous system (CNS) infection in immunocompromised patients [3]. The most common manifestation of listeriosis in the immunocompetent individuals is mild gastroenteritis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 15, 2024 Category: Hematology Authors: Dina Averbuch, Gloria Tridello, Lotus Wendel, Maija It älä-Remes, Ilana Oren, Michal Karas, Nicole Blijlevens, Yves Beguin, Annoek Broers, Elisabetta Calore, Chiara Cattaneo, Cecilia Isaksson, Christine Robin, Alain Gadisseur, Johan Maertens, Ann De Bec Tags: Infectious Disease Source Type: research